Skip to main content

Table 2 Baseline characteristics renal cell carcinoma† fisher’s exact test (reported as frequency (percent))

From: Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

  Clinical benefit (n=2) No clinical benefit (n=11) p-value
Age 47.0 (40.0) 53.0 (46.0-54.0) .641*
Male 2 (100%) 8 (72.7%) 1.0
Baseline ALC 1.55 (1.30) 1.40 (0.80-1.70) .641*
LDH 277.5 (158.0) 209.0 (151.0-286.0) .641*
Prior Treatments 1/2 (50%) 6/11 (54.5%) 1.0
Metastatic Subsets  
Distant Nodes 1 (50%) 2 (18.1%) .423
Lung +/− Distant Nodes 0 5 (45.5%) .487
Visceral 1 (50%) 4 (36.4%) 1.0
  1. *Mann–Whitney U (reported as median (interquartile range)).
  2. ALC: Absolute Lymphocyte Count.
  3. LDH: Lactate Dehydrogenase.